Eli Lilly Stock Near Crucial Support – Buy Signal?
Eli Lilly (LLY) stock should be on your watchlist. Here is why – it is currently trading in the support zone ($824.86 – $911.68), levels from which it has bounced meaningfully before. Since it first started trading, Eli Lilly stock received buying interest at this level 3 times and subsequently went on to generate 17.5% in average peak returns.
| Peak Return | Days to Peak Return | |
|---|---|---|
| 8/8/2024 | 13.7% | 22 |
| 4/17/2025 | 7.0% | 13 |
| 10/30/2025 | 31.6% | 26 |
Yet, a support zone alone isn’t enough; rebounds are more likely when fundamentals, sentiment, and market conditions line up. How does that look for LLY?
Rebound likely; GLP-1 strength and pipeline drive.
Lilly’s rebound is probable, underpinned by Mounjaro and Zepbound’s sustained demand driving significant revenue growth (42.6% YoY last quarter). Q1 earnings anticipate continued strength, supported by a 31.66% profit margin. Analyst average price targets, around $1200-$1230, suggest considerable upside from current levels. Strategic oncology acquisitions (Ajax, Kelonia) diversify pipeline beyond GLP-1s, mitigating single-product risk. Expansion of GLP-1 market, especially with oral Foundayo and Medicare access post-July 2026, provides significant tailwinds despite pricing scrutiny and competition.
- SCHD’s Holdings See Better Earnings Ahead
- Everyone Is Watching Applied Materials Stock’s AI Boom. The Real Story Is In The Supply Chain.
- The Real Price of Broadcom Stock Is Hidden Two Years Out
- Everyone Is Watching Cisco Stock’s AI Orders. Here’s The Number They Stopped Bragging About.
- Why SanDisk Stock’s Flat Production Is Its Most Bullish Signal
- The One Metric That Makes Costco Wholesale Stock Vulnerable
How Do LLY Financials Look Right Now?
- Revenue Growth: 44.7% LTM and 32.1% last 3-year average.
- Cash Generation: Nearly 9.2% free cash flow margin and 45.6% operating margin LTM.
- Recent Revenue Shocks: The minimum annual revenue growth in the last 3 years for LLY was 19.6%.
- Valuation: LLY stock trades at a PE multiple of 37.7
| LLY | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Pharmaceuticals | – |
| PE Ratio | 37.7 | 24.1 |
|
|
||
| LTM* Revenue Growth | 44.7% | 6.9% |
| 3Y Average Annual Revenue Growth | 32.1% | 5.5% |
| Min Annual Revenue Growth Last 3Y | 19.6% | 0.6% |
|
|
||
| LTM* Operating Margin | 45.6% | 18.6% |
| 3Y Average Operating Margin | 37.9% | 18.1% |
| LTM* Free Cash Flow Margin | 9.2% | 14.2% |
*LTM: Last Twelve Months | For more details on LLY fundamentals, read Buy or Sell LLY Stock.
And What If The Support Breaks?
LLY isn’t immune to big market hits. It fell 51% during the Global Financial Crisis and dropped 43% in the Dot-Com Bubble. Even the smaller shocks like the 2018 correction and the recent inflation jitters saw declines close to 18-19%. The Covid sell-off hit it for 22%. Solid fundamentals only go so far—when the market turns, LLY takes a hit like most others.
Still not sure about LLY stock? Consider the portfolio approach.
Portfolios Over Individual Stock Picks
Single stocks swing wildly, but staying invested matters. A well-built portfolio helps you stay invested, captures upside, and softens the blows from individual stocks.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? HQ Portfolio has posted more than 105% in cumulative return since inception, with less risk versus the benchmark index, as evident in HQ Portfolio performance metrics.